Prescription ·Strong evidence ·Reviewed May 2026
Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA) prescribed to lower very high triglycerides and to reduce the risk of cardiovascular events in selected patients already on statin therapy. Unlike combination fish oil products, it contains only EPA and no docosahexaenoic acid (DHA), which avoids the LDL-cholesterol increases sometimes seen with DHA-containing preparations. It is taken as oral capsules with food.
The bottom line
Evidence rating strong. Most-documented uses: adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglycerides at or above 500 mg/dl), reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, unstable angina) in statin-treated adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors. 3 sources indexed (2011–2019), with 5 interaction records on file.
Core mechanism
The exact mechanism for triglyceride lowering is not fully established but is thought to involve reduced hepatic synthesis and secretion of very-low-density lipoprotein (VLDL) triglycerides and enhanced clearance of triglycerides from circulating VLDL particles. EPA may inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, decrease hepatic lipogenesis, and increase fatty acid beta-oxidation. Beyond lipid effects, EPA is incorporated into cell membrane phospholipids where it modulates eicosanoid production, exerts anti-inflammatory and antithrombotic effects, may stabilize atherosclerotic plaque, and improves endothelial function, mechanisms proposed to underlie its cardiovascular benefit.1,2
Take with or at the end of a meal; absorption of the ester is improved by dietary fat and food helps ensure adequate exposure. Capsules must be swallowed whole.3
Fish Oil may increase bleeding tendency and can be a concern with Icosapent Ethyl when additional omega-3 products increase total antiplatelet exposure.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Ginkgo Biloba may increase bleeding tendency and can be a concern with Icosapent Ethyl when ginkgo is combined with omega-3 therapy or antithrombotic drugs.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Garlic Extract may increase bleeding tendency and can be a concern with Icosapent Ethyl when garlic is combined with omega-3 therapy or antithrombotic drugs.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Vitamin E may increase bleeding tendency and can be a concern with Icosapent Ethyl when high-dose vitamin E is combined with omega-3 therapy or antithrombotic drugs.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Icosapent ethyl is a fatty acid ester that requires dietary fat for absorption, and fat-soluble vitamin K1 is similarly best absorbed with a fat-containing meal. Taking them together with food can optimize absorption of both, though there is no harmful interaction.
Recommendation: Take icosapent ethyl with food as directed. If you supplement vitamin K1, taking it with the same fat-containing meal is reasonable. If you also take warfarin, keep your vitamin K intake consistent and discuss any changes with your clinician.
Numbered references. Citations throughout the page link here.
Among 8,179 statin-treated patients, icosapent ethyl reduced the primary composite endpoint by approximately 25% versus placebo, with a modest increase in atrial fibrillation and a nonsignificant trend toward more serious bleeding.
In patients with triglycerides 500 mg/dL or higher, icosapent ethyl 4 g/day significantly reduced triglycerides by about 33% without increasing LDL cholesterol relative to placebo.
Labeling specifies a 4 g/day dose taken with food, indications for severe hypertriglyceridemia and cardiovascular risk reduction, and warnings regarding atrial fibrillation/flutter and bleeding.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
